Breaking News, Collaborations & Alliances

Genmab Achieves $20M Janssen Milestone

The daratumumab collaboration progress is based on a study of the drug in a disease other than multiple myeloma

Genmab’s DARZALEX (daratumumab) collaboration partner, Janssen Biotech, has triggered a $20 million milestone payment. The milestone relates to progress in the ongoing Phase III ANDROMEDA study of daratumumab in combination with cyclophosphamide, bortezomib and dexamethasone in amyloidosis.   Daratumumab is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters